Arcellx (ACLX) Competitors $79.15 +0.93 (+1.19%) Closing price 04:00 PM EasternExtended Trading$79.16 +0.01 (+0.01%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACLX vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, ROIV, ELAN, VRNA, and MRNAShould you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Arcellx vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen BridgeBio Pharma Roivant Sciences Elanco Animal Health Verona Pharma PLC American Depositary Share Moderna Arcellx (NASDAQ:ACLX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Do insiders and institutionals have more ownership in ACLX or SMMT? 96.0% of Arcellx shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 8.4% of Arcellx shares are held by insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor ACLX or SMMT? In the previous week, Summit Therapeutics had 7 more articles in the media than Arcellx. MarketBeat recorded 14 mentions for Summit Therapeutics and 7 mentions for Arcellx. Arcellx's average media sentiment score of 1.03 beat Summit Therapeutics' score of 0.70 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ACLX or SMMT? Arcellx presently has a consensus target price of $114.31, suggesting a potential upside of 44.42%. Summit Therapeutics has a consensus target price of $31.87, suggesting a potential upside of 66.41%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Summit Therapeutics 4 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.56 Is ACLX or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Arcellx's return on equity of -43.04% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-329.93% -43.04% -27.41% Summit Therapeutics N/A -208.64%-181.28% Which has more risk and volatility, ACLX or SMMT? Arcellx has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500. Which has higher valuation and earnings, ACLX or SMMT? Arcellx has higher revenue and earnings than Summit Therapeutics. Arcellx is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$107.94M40.67-$107.35M-$3.42-23.14Summit Therapeutics$700K20,322.25-$221.32M-$1.01-18.96 SummaryArcellx beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks. Get Arcellx News Delivered to You Automatically Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACLX vs. The Competition Export to ExcelMetricArcellxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.39B$3.13B$5.73B$10.43BDividend YieldN/A2.36%5.61%4.58%P/E Ratio-23.1421.0476.4226.62Price / Sales40.67448.77551.00126.98Price / CashN/A44.8325.8131.15Price / Book9.419.7813.626.47Net Income-$107.35M-$52.73M$3.29B$271.57M7 Day Performance2.33%2.40%1.67%2.83%1 Month Performance11.04%4.69%4.04%7.27%1 Year Performance-7.94%16.28%80.70%26.07% Arcellx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACLXArcellx2.3265 of 5 stars$79.15+1.2%$114.31+44.4%-9.7%$4.39B$107.94M-23.1480Positive NewsSMMTSummit Therapeutics3.1769 of 5 stars$18.94flat$33.79+78.4%-21.7%$14.07B$700K-18.75110RDYDr. Reddy's Laboratories2.7533 of 5 stars$14.64-0.2%$16.95+15.8%-7.1%$12.24B$3.81B22.1727,811Positive NewsASNDAscendis Pharma A/S2.9954 of 5 stars$194.62-0.5%$244.36+25.6%+29.9%$11.97B$393.54M-37.721,017VTRSViatris1.2962 of 5 stars$9.60-3.6%$10.40+8.3%-14.0%$11.61B$14.74B-3.3132,000High Trading VolumeQGENQiagen4.3738 of 5 stars$45.39+0.2%$49.69+9.5%+4.7%$10.07B$1.98B26.825,765BBIOBridgeBio Pharma4.5043 of 5 stars$51.47+0.5%$63.94+24.2%+92.7%$9.79B$221.90M-12.58400ROIVRoivant Sciences3.439 of 5 stars$13.95-0.9%$17.67+26.6%+24.8%$9.61B$29.05M-19.93860Positive NewsAnalyst RevisionELANElanco Animal Health2.6079 of 5 stars$18.63+0.5%$17.33-6.9%+35.6%$9.21B$4.44B21.669,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.0446 of 5 stars$106.37-0.1%$109.00+2.5%+254.3%$9.17B$42.28M-107.4430Positive NewsMRNAModerna4.4633 of 5 stars$23.88+1.6%$41.81+75.1%-59.6%$9.15B$3.24B-3.175,800Trending News Related Companies and Tools Related Companies SMMT Competitors RDY Competitors ASND Competitors VTRS Competitors QGEN Competitors BBIO Competitors ROIV Competitors ELAN Competitors VRNA Competitors MRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACLX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACLX Stock Alerts